Manu Chakravarthy
Chief Tech/Sci/R&D Officer chez Carmot Therapeutics, Inc.
Postes actifs de Manu Chakravarthy
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Chief Tech/Sci/R&D Officer | 01/03/2021 | - |
Historique de carrière de Manu Chakravarthy
Anciens postes connus de Manu Chakravarthy
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AXCA HEALPAR | Chief Tech/Sci/R&D Officer | 01/08/2017 | 05/03/2021 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/08/2015 | 01/06/2017 |
Formation de Manu Chakravarthy
| Saint John's University | Undergraduate Degree |
| University of Texas Graduate School of Biomedical Sciences | Doctorate Degree |
| The University of Texas Medical School At Houston | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| AXCA HEALPAR | Health Technology |
| Entreprise privées | 1 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Bourse
- Insiders
- Manu Chakravarthy
- Expérience
